Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Van Cleef Asset Management Inc

Van Cleef Asset Management Inc increased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 23.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,576 shares of the biopharmaceutical company’s stock after acquiring an additional 3,299 shares during the quarter. Van Cleef Asset Management Inc’s holdings in Bristol-Myers Squibb were worth $902,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Riversedge Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 3.2% during the third quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 178 shares during the last quarter. Vicus Capital grew its holdings in shares of Bristol-Myers Squibb by 3.9% during the third quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 179 shares during the last quarter. Lindbrook Capital LLC grew its holdings in shares of Bristol-Myers Squibb by 2.3% during the third quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 182 shares during the last quarter. Addison Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 6.6% during the third quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 192 shares during the last quarter. Finally, Symphony Financial Ltd. Co. grew its holdings in shares of Bristol-Myers Squibb by 4.1% during the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 194 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on BMY shares. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Down 8.6 %

Shares of NYSE:BMY traded down $4.18 during mid-day trading on Thursday, reaching $44.68. 45,047,382 shares of the stock were exchanged, compared to its average volume of 15,901,512. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock’s 50 day simple moving average is $51.22 and its 200-day simple moving average is $51.31. The company has a market cap of $90.56 billion, a P/E ratio of 11.70, a P/E/G ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $44.37 and a one year high of $69.74.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $2.05 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.37%. Bristol-Myers Squibb’s dividend payout ratio is 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.